Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
211. |
ECCT/20/11/04 | FAST Study Assessments of the EFficacy, the onset-of-Action and the Safety of Tot'héma® in adults with moderate iron deficiency anaemia |
Principal Investigator(s) 1. Naftali Wasindi Busakhala 2. Otieno Odhiambo Fredrick Site(s) in Kenya 1. MOI University Teaching and Referral Hospita (Nandi county) 2. UNIM Research and Training Centre (Kisumu county) 3. Kenyatta National Hospital (Nairobi City county) |
View |
212. |
ECCT/20/11/03 | IMR-SCD-301 A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba Site(s) in Kenya 1. Kenya Medical Research Institute-Kondele Children\'s Hospital (Kisumu county) 2. The Center For Respiratory Disease Research/KEMRI (Nairobi City county) 3. Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
213. |
ECCT/20/11/02 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (IAVI C100) |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya 1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county) 2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county) |
View |
214. |
ECCT/20/11/01 | GC vaccine study in kenya Protocol Title: USE OF BEXSERO IMMUNIZATION TO DETECT CROSS REACTIVE ANTIGENS AND ANTI-GONOCOCCAL ANTIBODIES IN KEY POPULATIONS IN KENYA. |
Principal Investigator(s) 1. Prof. Eduard Sanders Site(s) in Kenya The KEMRI-Wellcome Trust Research Programme (KWTRP) Kenya Medical Research Institute (KEMRI) / Wellcome Trust Centre for Geographic Medicine Research – Coast (CGMRC) |
View |
215. |
ECCT/20/10/04 | yellow fever vaccine CVIA 079 A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079. |
Principal Investigator(s) 1. Dr. Deborah Langat Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
View |